77 例多原发癌患者的临床病理特征和预后分析。

Clinicopathological features and prognostic analysis of 77 patients with multiple primary cancers.

机构信息

Department of Oncology, Affiliated Dongguan People's Hospital, Southern Medical University, Dongguan 523000, China.

出版信息

J BUON. 2020 Jul-Aug;25(4):2110-2116.

Abstract

PURPOSE

The purpose of this study was to analyze the characteristics, diagnosis and treatment principles and prognosis of multiple primary cancers (MPC).

METHODS

A total of 77 patients with MPC admitted in the Central Hospital of Changsha from December 2013 to December 2018 were enrolled in this retrospective analysis. The survival of these 77 patients with complete follow-up data was calculated.

RESULTS

There were 77 patients with multiple primary cancers, including 70 patients with double primary cancers, 6 patients with three primary cancers, and 1 patient with four primary cancers. Among the 77 MPC patients, there were 4 synchronous carcinomas (SC), 58 metachronous carcinomas (MC), and 15 unknown cases. The 3, 5, and 10-year overall survival rates of 77 patients with follow-up data were 86.5%, 18.2%, and 12.9%, respectively. The median survival time of 4 SC and 58 MC patients was 12 months and 108 months, respectively. The median survival time was 48.5 months in 23 patients with an interval of less than 5 years, and 108 months in 29 patients with first and second primary cancers whose interval was more than 5 years. The median survival time of 26 patients with second primary lung cancer was 84 months, and that of 23 patients with second primary non-lung cancer was 156 months.

CONCLUSIONS

MPCs are more likely to occur in the colorectum, and the prognosis of patients with metachronous cancer is better than that of patients with synchronous cancer. The longer the interval between two cancers, the better the prognosis will be. The prognosis of the second primary non-lung cancer patients is better than that of the lung cancer patients.

摘要

目的

本研究旨在分析多原发癌（MPC）的特点、诊断、治疗原则及预后。

方法

回顾性分析 2013 年 12 月至 2018 年 12 月在长沙市中心医院收治的 77 例 MPC 患者的临床资料，随访并计算生存情况。

结果

77 例 MPC 患者中，双原发癌 70 例，三原发癌 6 例，四原发癌 1 例；4 例为同时性多原发癌（SC），58 例为异时性多原发癌（MC），15 例为不明时间顺序的多原发癌。77 例患者中，3、5、10 年总生存率分别为 86.5%、18.2%、12.9%。4 例 SC 和 58 例 MC 患者的中位生存时间分别为 12 个月和 108 个月；23 例 5 年以内间隔的 MC 患者和 29 例间隔 5 年以上的首发和第二原发癌患者的中位生存时间分别为 48.5 个月和 108 个月；26 例第二原发肺癌患者的中位生存时间为 84 个月，23 例第二原发非肺癌患者的中位生存时间为 156 个月。